Want to see SE:INIT full AI Analyst Report?
INIT Stock Chart & Stats
kr2.29
kr0.25(10.92%)
At close: 4:00 PM EDT
kr2.29
kr0.25(10.92%)
Day’s Range― - ―
52-Week Rangekr2.14 - kr4.07
Previous CloseN/A
Volume40.71K
Average Volume (3M)133.41K
Market Cap
kr156.07M
Enterprise Valuekr121.90M
Total Cash (Recent Filing)kr19.90M
Total Debt (Recent Filing)kr7.56M
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding68,452,890
10 Day Avg. Volume157,519
30 Day Avg. Volume133,406
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)4.31
Price to Sales (P/S)0.00
P/FCF Ratio-7.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.63
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Clinical-stage PipelineA narrow, clinical-stage focus on small-molecule therapies for a defined unmet need (male sexual health) concentrates R&D resources, reduces discovery-stage risk, and increases attractiveness for partnering or licensing. This structural clarity supports milestone-driven value creation over months.
Modest Leverage And Positive EquityLow debt levels reduce insolvency and interest burden, giving management optionality to fund clinical programs via equity or partnerships. Positive equity provides a cushion for near-term operations and supports continued R&D investment without immediate solvency stress.
Free Cash Flow Trend ImprovementAn improving free cash flow trend signals progress toward better cash efficiency or lower incremental spend per development milestone. While still negative, this structural improvement can extend runway and reduce the cadence or magnitude of external financing needs over the medium term.
Bears Say
Pre-revenue With Widening LossesOperating without revenue and with materially larger losses creates persistent funding dependency. Over time this increases dilution risk, limits reinvestment capacity, and leaves commercial success contingent on clinical/regulatory milestones that can be binary and time-consuming.
Sustained Cash Burn And Negative Operating Cash FlowOngoing negative operating cash flow indicates the company must access capital markets or partners repeatedly. Structurally, sustained cash burn can force unfavorable financing, slow development if capital is scarce, and pressure prioritization of programs rather than an optimal R&D plan.
Declining Equity And Negative Returns On EquityA shrinking equity base and negative ROE reflect capital erosion from losses, weakening the balance-sheet buffer. This durable weakness raises the probability of dilutive financings or strategic exits, and diminishes long-term investor returns absent successful clinical/partnering outcomes.
INIT FAQ
What was Initiator Pharma A/S’s price range in the past 12 months?
Initiator Pharma A/S lowest stock price was kr2.14 and its highest was kr4.07 in the past 12 months.
What is Initiator Pharma A/S’s market cap?
Initiator Pharma A/S’s market cap is kr156.07M.
When is Initiator Pharma A/S’s upcoming earnings report date?
Initiator Pharma A/S’s upcoming earnings report date is Aug 21, 2026 which is in 18 days.
How were Initiator Pharma A/S’s earnings last quarter?
Initiator Pharma A/S released its earnings results on May 08, 2026. The company reported -kr0.242 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.242.
Is Initiator Pharma A/S overvalued?
According to Wall Street analysts Initiator Pharma A/S’s price is currently Overvalued.
Does Initiator Pharma A/S pay dividends?
Initiator Pharma A/S does not currently pay dividends.
What is Initiator Pharma A/S’s EPS estimate?
Initiator Pharma A/S’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Initiator Pharma A/S have?
Initiator Pharma A/S has 68,452,890 shares outstanding.
What happened to Initiator Pharma A/S’s price movement after its last earnings report?
Initiator Pharma A/S reported an EPS of -kr0.242 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.297%.
Which hedge fund is a major shareholder of Initiator Pharma A/S?
Currently, no hedge funds are holding shares in SE:INIT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Initiator Pharma A/S
Initiator Pharma A/S is a clinical-stage life sciences firm dedicated to discovering therapeutic solutions for critical unmet medical needs affecting the central and peripheral nervous systems. Its development pipeline features several clinical-phase compounds: IP2018, a monoamine reuptake inhibitor aimed at psychogenic erectile dysfunction; IPED2015, designed to address organic erectile dysfunction; and IPTN2021, an orphan drug candidate for severe neuropathic pain. Additionally, the company holds early-stage assets, including IPNP2015 for chronic pain management and IPDP2015 for depression. Established in 2016, Initiator Pharma A/S maintains its headquarters in Copenhagen, Denmark.